Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25372775 | 1.00 | FFAR3 (0.39) | FFAR3ARG1ARG2CYP2C19PARP1 | |
| SCHEMBL53553 | 1.00 | FFAR3 (0.39) | FFAR3ARG1ARG2CYP2C19PARP1 | |
| Hydrochloric Acid SCHEMBL16584573 | 0.98 | FFAR3 (0.37) | FFAR3ARG1ARG2CYP2C19 | |
| Hydrochloric Acid SCHEMBL5968897 | 0.98 | FFAR3 (0.37) | FFAR3ARG1ARG2CYP2C19 | |
| Hydrochloric Acid SCHEMBL927105 | 0.98 | FFAR3 (0.37) | FFAR3ARG1ARG2CYP2C19 | |
| SCHEMBL697443 | 0.93 | — | — | |
| SCHEMBL573927 | 0.93 | — | — | |
| SCHEMBL3325667 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL17393208 | 0.91 | FFAR3 (0.39) | FFAR3ARG1ARG2PARP1 | |
| Bromide SCHEMBL14659502 | 0.91 | FFAR3 (0.39) | FFAR3ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-103702980-B | Cyclic amine derivatives as EP 4 receptor antagonists | 罗达制药生物技术有限责任公司 | 2016-10-05 | — | — | CN | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| EP-2729445-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-10-21 | — | — | EP | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| EP-2729445-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2014-05-14 | — | — | EP | disclosed |
| CN-103702980-A | Cyclic amine derivatives as EP4Receptor antagonists | ROTTAPHARM SPA | 2014-04-02 | — | — | CN | disclosed |
| WO-2013004290-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | FFAR3 228/4885ARG1 323/4885ARG2 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.